The Journal of Pediatrics
Volume 157, Issue 2 , Pages 282-287 , August 2010

The Efficacy and Safety of the Novel Aldosterone Antagonist Eplerenone in Children with Hypertension: A Randomized, Double-Blind, Dose-Response Study

  • Jennifer S. Li, MD, MHS

      Affiliations

    • Division of Pediatric Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationReprint requests: Jennifer S. Li MD, MHS, Box 3090, Duke University Medical Center, Durham, NC 27710.
    • ,
  • Joseph T. Flynn, MD, MS

      Affiliations

    • Division of Nephrology, Seattle Children's Hospital, Seattle, WA
    • ,
  • Ronald Portman, MD

      Affiliations

    • Bristol-Myers Squibb, Princeton, NJ
    • ,
  • Ira Davis, MD

      Affiliations

    • Baxter Healthcare, McGaw Park, IL
    • ,
  • Masayo Ogawa, MD

      Affiliations

    • Pfizer Global Research and Development, New London, CT
    • New York, NY
    • ,
  • Harry Shi, MA

      Affiliations

    • Pfizer Global Research and Development, New London, CT
    • New York, NY
    • ,
  • Milton L. Pressler, MD

      Affiliations

    • Pfizer Global Research and Development, New London, CT
    • New York, NY

Received 7 October 2009 ,Revised 29 December 2009 ,Accepted 22 February 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Funded by Pfizer, Inc. J.L. is a consultant to Pfizer, Inc and Sanofi-Aventis. J.F. is a consultant to Pfizer, Inc, Gilead Sciences, Inc, Shire Pharmaceuticals, and Novartis Pharmaceuticals. M.P., M.O., and H.S. were employees of Pfizer, Inc during the study. The other authors declare no conflicts of interest.

 Registered at clinicaltrials.gov (NCT10014589).

PII: S0022-3476(10)00166-6

doi: 10.1016/j.jpeds.2010.02.042

The Journal of Pediatrics
Volume 157, Issue 2 , Pages 282-287 , August 2010

Article Tools

* Image Usage & Resolution